Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation

被引:21
|
作者
Pastori, Daniele [1 ,2 ]
Farcomeni, Alessio [3 ]
Saliola, Mirella [1 ]
Del Sole, Francesco [1 ]
Pignatelli, Pasquale [1 ]
Violi, Francesco [1 ]
Lip, Gregory Y. H. [2 ,4 ]
机构
[1] Sapienza Univ Rome, Dept Internal Med & Med Specialties, Clin Med 1, Atherothrombosis Ctr, Rome, Italy
[2] Univ Birmingham, Inst Cardiovasc Sci, Birmingham, W Midlands, England
[3] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Rome, Italy
[4] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark
关键词
Atrial fibrillation; Anticoagulation; Vitamin K antagonists; Time in therapeutic range; Cardiovascular events; PROTON PUMP INHIBITORS; ANTICOAGULATION CONTROL; ORAL ANTICOAGULATION; WARFARIN; QUALITY; RISK; EFFICACY; ASPIRIN; STROKE; SAFETY;
D O I
10.1016/j.ejim.2018.04.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Optimal time in therapeutic range (TTR) of vitamin K antagonists (VKAs) is crucial for cardiovascular events (CVEs) prevention in non-valvular atrial fibrillation (NVAF). The relationship between temporal changes of TTR and the incidence of CVEs has been poorly investigated. We investigated 1) temporal trends of TTR in a long-term follow-up of NVAF patients; 2) the incidence of CVEs according to changes of TTR. Methods: Prospective observational study including 1341 NVAF outpatients (mean age 73.5 years, 42.5% male) starting VKAs. Patients were divided into 4 groups: Group 0: Optimal TTR, consistently >= 70% (n = 241); Group 1: Temporally worsening TTR, from above to below 70% (n = 263); Group 2: Temporally improving TTR, from below to above 70% (n = 270); Group 3: Suboptimal TTR, consistently < 70% (n = 567). Results: In a mean follow-up of 37.7 months (4214.2 patient-years), 108 CVEs occurred (2.6%/year). Survival analysis showed a graded increased risk of CVEs in relation to temporal changes in TTR, with the worst outcomes in Groups 1 and 3 (log-rank test p = 0.013). Multivariable Cox proportional hazards regression analysis showed that Group 1 vs. 0 (HR: 2.096; 95%CI 1.061-4.139, p = 0.033), Group 3 vs. 0 (HR: 2.292; 95%CI 1.205-4.361, p = 0.011), CHA(2)DS(2)VASc score (HR:1.316; 95%CI 1.153-1.501, p < 0.001) and PPIs (HR:0.453; 95%CI 0.285-0.721, p = 0.001) were independently associated with CVEs. Conclusion: A decrease of TTR < 70% over time is observed in almost 20% of NVAF patients. Patients with worsening TTR temporally (ie. from initially above 70% to below 70%) have similar risk of CVEs of patients with consistently suboptimal anticoagulation.
引用
收藏
页码:34 / 39
页数:6
相关论文
共 50 条
  • [1] PROVIDER INTERPRETATION AND UTILIZATION OF TIME IN THERAPEUTIC RANGE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Brunton, Nichole
    Rouzbehani, Jahangir
    Sostin, Oleg
    Wakefield, Dorothy
    Galin, Ira
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2104 - 2104
  • [2] Key Factors That Lower Time in Therapeutic Range of Warfarin in Patients with Non-Valvular Atrial Fibrillation
    Tanaka, T.
    Ihara, M.
    Yamagami, H.
    Toyoda, K.
    Nagatsuka, K.
    [J]. CEREBROVASCULAR DISEASES, 2015, 40 : 70 - 70
  • [3] Vitamin e serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation
    Cangemi, R.
    Pignatelli, P.
    Pastori, D.
    Carnevale, R.
    Basili, S.
    Ferro, D.
    Loffredo, L.
    Pignataro, F. S.
    Di Santo, S.
    Violi, F.
    [J]. EUROPEAN HEART JOURNAL, 2013, 34 : 1037 - 1038
  • [4] Flow-mediated dilation is associated with cardiovascular events in non-valvular atrial fibrillation patients
    Perri, L.
    Pastori, D.
    Catasca, E.
    Bucci, T.
    Loffredo, L.
    Pignatelli, P.
    Violi, F.
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 : 431 - 432
  • [5] Flow-mediated dilation is associated with cardiovascular events in non-valvular atrial fibrillation patients
    Perri, Ludovica
    Pastori, Daniele
    Pignatelli, Pasquale
    Violi, Francesco
    Loffredo, Lorenzo
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 179 : 139 - 143
  • [6] Temporal trends in thromboembolism and bleeding in patients with non-valvular atrial fibrillation between 1996 and 2011
    Hansen, P. W.
    Gislason, G.
    Torp-Pedersen, C.
    Andersson, C.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 1084 - 1084
  • [7] Venous Thromboembolism and Atherosclerotic Events in Patients With Non-Valvular Atrial Fibrillation
    Thomopoulos, Costas
    [J]. ANGIOLOGY, 2022, 73 (05) : 393 - 394
  • [8] Impact of age on thromboembolic events in patients with non-valvular atrial fibrillation
    Kim, Yun Gi
    Choi, Jong-Il
    Boo, Ki Yung
    Kim, Do Young
    Hong, Yeji
    Kim, Min Sun
    Lee, Kwang-No
    Shim, Jaemin
    Kim, Jin Seok
    Kim, Young-Hoon
    [J]. CLINICAL CARDIOLOGY, 2020, 43 (01) : 78 - 85
  • [9] TIME IN THERAPEUTIC RANGE ≥55% VERSUS &lt;55% ON WARFARIN THERAPY OUTCOMES IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS
    An, Jaejin
    Lang, Daniel
    Fang, Niu
    Jazdzewski, Kristin
    Le, Paul
    Rashid, Nazia
    Meissner, Brian
    Mendes, Robert
    Dills, Diana
    Ershoff, Dan
    Borok, Gerald
    Bruno, Amanda
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) : A359 - A359
  • [10] Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores
    Marco Proietti
    Keitaro Senoo
    Deirdre A. Lane
    Gregory Y. H. Lip
    [J]. Scientific Reports, 6